利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.039 秒)

    Methods of treating cancer and other conditions or disease states using LFMAU and LDT
    2.
    发明授权
    Methods of treating cancer and other conditions or disease states using LFMAU and LDT 有权
    使用LFMAU和LDT治疗癌症和其他病症或疾病状态的方法

    公开(公告)号：US08207143B2

    公开(公告)日：2012-06-26

    申请号：US13004401

    申请日：2011-01-11

    申请人： Yung-chi Cheng

    发明人： Yung-chi Cheng

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： A61K31/70 ,  C07H19/00 ,  C07H19/048

    摘要： The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R8 is independently H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.

    摘要翻译： 本发明涉及以下式（I）化合物用于治疗肿瘤，癌症和过度增生性疾病等疾病或疾病状态的用途：其中X是H或F; R 1和R 2独立地为H，酰基，C 1 -C 20烷基或醚基，磷酸酯，二磷酸酯，三磷酸酯或磷酸二酯基，（A）或（B）基团; 其中Nu是生物活性化合物如抗癌剂，抗病毒剂或抗高血压增殖化合物的基团，使得所述生物活性剂的氨基或羟基与相邻部分形成磷酸酯，氨基磷酸酯，碳酸酯或氨基甲酸酯基团; 每个R 8独立地为H或C 1 -C 20烷基或醚基，优选C 1 -C 12烷基; k为0-12，优选为0-2; 及其药学上可接受的盐。

    HINGE
    3.
    发明申请
    HINGE 有权
    合页

    公开(公告)号：US20120090134A1

    公开(公告)日：2012-04-19

    申请号：US12956102

    申请日：2010-11-30

    申请人： YUNG-CHI CHENG ,  CHING-FENG HSIEH

    发明人： YUNG-CHI CHENG ,  CHING-FENG HSIEH

    IPC分类号： E05D7/04

    CPC分类号： E05D11/1007 ,  E05Y2600/51 ,  E05Y2800/692 ,  Y10T16/5327 ,  Y10T16/53607 ,  Y10T16/5361 ,  Y10T16/5362 ,  Y10T16/5409 ,  Y10T16/551 ,  Y10T16/5535

    摘要： A hinge, configured to be stably positioned by a simple mechanism and advantageously characterized by ease of installation and uninstallation, includes a first connection member and a second connection member. The first connection member includes a first fixing unit and a support unit. The first fixing unit has a first fixing side and a connecting side. The support unit is connected to the connecting side, and has a cylindrical receiving chamber and a via in communication with the cylindrical receiving chamber. The via is penetrable by a rod-shaped tool. The second connection member includes a second fixing unit and a post connected to the second fixing unit. The second fixing unit has a second fixing side. The post is removably disposed in the cylindrical receiving chamber and has a positioning hole for receiving an end portion of the rod-shaped tool when aligned with the via.

    摘要翻译： 构造成通过简单的机构稳定地定位并且有利地特征在于易于安装和卸载的铰链包括第一连接构件和第二连接构件。 第一连接构件包括第一固定单元和支撑单元。 第一固定单元具有第一固定侧和连接侧。 支撑单元连接到连接侧，并且具有与圆筒形容纳室连通的圆柱形容纳室和通孔。 通孔可由杆状工具穿透。 第二连接构件包括第二固定单元和连接到第二固定单元的柱。 第二固定单元具有第二固定侧。 柱可移除地设置在圆柱形容纳室中，并且具有定位孔，用于当与通孔对准时接收杆状工具的端部。

    Methods of treating cancer and other conditions or disease states using LFMAU and LDT
    4.
    发明授权
    Methods of treating cancer and other conditions or disease states using LFMAU and LDT 有权
    使用LFMAU和LDT治疗癌症和其他病症或疾病状态的方法

    公开(公告)号：US07879816B2

    公开(公告)日：2011-02-01

    申请号：US11921194

    申请日：2006-06-05

    申请人： Yung-chi Cheng

    发明人： Yung-chi Cheng

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： A61K31/70 ,  C07H19/00 ,  C07H19/048

    摘要： The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R8 is independently H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.

    摘要翻译： 本发明涉及以下式（I）化合物用于治疗肿瘤，癌症和过度增生性疾病等疾病或疾病状态的用途：其中X是H或F; R 1和R 2独立地为H，酰基，C 1 -C 20烷基或醚基，磷酸酯，二磷酸酯，三磷酸酯或磷酸二酯基，（A）或（B）基团; 其中Nu是生物活性化合物如抗癌剂，抗病毒剂或抗高血压增殖化合物的基团，使得所述生物活性剂的氨基或羟基与相邻部分形成磷酸酯，氨基磷酸酯，碳酸酯或氨基甲酸酯基团; 每个R 8独立地为H或C 1 -C 20烷基或醚基，优选C 1 -C 12烷基; k为0-12，优选为0-2; 和其药学上可接受的盐。

    Compounds and methods to increase anti-P-glycoprotein activity of baicalein by alkylation on the A ring
    5.
    发明授权
    Compounds and methods to increase anti-P-glycoprotein activity of baicalein by alkylation on the A ring 有权
    通过在A环上烷基化增加黄芩素抗P-糖蛋白活性的化合物和方法

    公开(公告)号：US07875650B2

    公开(公告)日：2011-01-25

    申请号：US10586822

    申请日：2005-01-31

    申请人： Yung-chi Cheng ,  Yashang Lee ,  Hosup Yeo

    发明人： Yung-chi Cheng ,  Yashang Lee ,  Hosup Yeo

    IPC分类号： A61K31/35

    CPC分类号： C07D311/32 ,  C07D311/30

    摘要： The present invention is directed to analogs of baicalein according to formula (I): where R5 is H, (C1-C12)alkyl, (C2-C13)acyl, or an optionally substituted phenyl or benzyl group, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group; R6 and R7 are each independently H, (C1-C12)alkyl, (C2-C13)acyl, or an optionally substituted phenyl or benzyl or together form a —OCR1R2O— group wherein each of R1 and R2 is independently H, a C1-C3 alkyl group or an optionally substituted phenyl or benzyl group; and R8 is H, OH, an O-acyl group, a C1,-C4 alkyl or alkoxy group, F, Cl, Br or I, or a pharmaceutically acceptable salt thereof, which exhibit anti-P-glycoprotein activity and methods of enhancing the bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme, especially CYP450 3A4 enzyme. Pharmaceutical compositions based upon these novel derivatives according to the present invention are also described herein.

    摘要翻译： 本发明涉及式（I）的黄芩素类似物：其中R 5是H，（C 1 -C 12）烷基，（C 2 -C 13）酰基或任意取代的苯基或苄基，酰基，C1 -C 20烷基或醚基，磷酸酯，二磷酸酯，三磷酸酯或磷酸二酯基; R 6和R 7各自独立地为H，（C 1 -C 12）烷基，（C 2 -C 13）酰基或任选取代的苯基或苄基或一起形成-OCR 1 R 2 O-基团，其中R 1和R 2各自独立地为H， C3烷基或任选取代的苯基或苄基; R8为H，OH，O-酰基，C1-C4烷基或烷氧基，F，Cl，Br或I或其药学上可接受的盐，其具有抗P-糖蛋白活性和增强的方法 通过抑制P-糖蛋白170（P-gp 170）和/或CYP450酶，特别是CYP450 3A4酶，活性化合物，特别是口服给药化合物的生物利用度。 基于本发明的这些新型衍生物的药物组合物也在本文中描述。

    Methods of Treating Cancer and Other Conditions or Disease States Using Lfmau and Ldt
    7.
    发明申请
    Methods of Treating Cancer and Other Conditions or Disease States Using Lfmau and Ldt 有权
    使用Lfmau和Ldt治疗癌症和其他病症或疾病状态的方法

    公开(公告)号：US20080292687A1

    公开(公告)日：2008-11-27

    申请号：US11921194

    申请日：2006-06-05

    申请人： Yung Chi Cheng

    发明人： Yung Chi Cheng

    IPC分类号： A61K9/127 ,  A61K31/7072 ,  C07H7/06 ,  A61P35/00 ,  A61K38/20

    CPC分类号： A61K31/70 ,  C07H19/00 ,  C07H19/048

    摘要： The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R1 and R2 are independently H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R8 is independently H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof.

    摘要翻译： 本发明涉及以下式（I）化合物用于治疗肿瘤，癌症和过度增生性疾病等疾病或疾病状态的用途：其中X是H或F; R 1和R 2独立地为H，酰基，C 1 -C 20烷基或醚基，磷酸酯，二磷酸酯，三磷酸酯或磷酸二酯基，（A）或（B）基团; 其中Nu是生物活性化合物如抗癌剂，抗病毒剂或抗高血压增殖化合物的基团，使得所述生物活性剂的氨基或羟基与相邻部分形成磷酸酯，氨基磷酸酯，碳酸酯或氨基甲酸酯基团; 每个R 8独立地为H或C 1 -C 20烷基或醚基，优选C 1 -C 12烷基; k为0-12，优选为0-2; 及其药学上可接受的盐。